The clinical trial application for BaiKe Bio-Adsorbed Cell-Free Two-Component Diphtheria-Tetanus Combined Vaccine has been approved
November 13, 2025
Source: drugdu
61
On November 12th, BaiKe Biotechnology(688276) issued an announcement stating that it recently received the "Drug Clinical Trial Approval Notice" from the National Medical Products Administration for its adsorbed acellular pertussis (two-component) diphtheria-tetanus combined vaccine (for adults and adolescents).
This vaccine is designed to prevent pertussis, diphtheria, and tetanus, and is intended for individuals aged 10 years and older. The approval notification number is 2025LP02992, the acceptance number is CXSL2500724, and the approval date is November 11, 2025.
The announcement also mentioned that there is some uncertainty regarding the conduct of subsequent clinical trials, and there is also uncertainty regarding whether commercial objectives can ultimately be achieved.
In the first three quarters of 2025, BaiKe Bio achieved revenue of 474 million yuan and net profit attributable to the parent company of -158 million yuan.
https://finance.eastmoney.com/a/202511123562254094.html
By editor
Copyright©2025 Ddu. All rights reserved.
Read more on
- Breaking the Mold and Forging a New Path! From Insulin Technology Pioneer to Global Innovation Competitor December 4, 2025
- A subsidiary of Kingfriend Pharmaceutical Co., Ltd. has received FDA approval for its self-developed injectable dapavancin December 4, 2025
- Major ophthalmic new drug successfully completed Phase III trials December 4, 2025
- Simcere Pharmaceutical and Wangshan Wangshui have reached an exclusive licensing agreement for deuterium remidevir hydrobromide for new indications such as RSV infection December 4, 2025
- SAL0140 tablets approved for clinical trials for the treatment of chronic kidney disease December 4, 2025
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
